| abstract |
In some aspects, the invention relates to an antibody-drug conjugate comprising an antibody, a linker, and at least two active agents. In a preferred embodiment, the linker comprises a peptide sequence of multiple amino acids and at least two active agents are covalently linked to the side chains of the amino acids. The antibody-drug complex may contain a self-destructing group, preferably two self-destructing groups. The linker can include an O-substituted oxime, for example, the oxygen atom of the oxime is replaced with a group that covalently connects the oxime to the active agent, and the carbon atom of the oxime is replaced with a group that covalently connects the oxime to the antibody. Has been. [Selection] Figure 1 |